These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19653696)

  • 41. Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS).
    Fischer JJ; Graebner Baessler OY; Dalhoff C; Michaelis S; Schrey AK; Ungewiss J; Andrich K; Jeske D; Kroll F; Glinski M; Sefkow M; Dreger M; Koester H
    J Proteome Res; 2010 Feb; 9(2):806-17. PubMed ID: 20028079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteome-wide identification of staurosporine-binding kinases using capture compound mass spectrometry.
    Fischer JJ; Graebner Neé Baessler OY; Dreger M
    Methods Mol Biol; 2012; 795():135-47. PubMed ID: 21960220
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteomic characterization of human platelet-derived microparticles.
    Capriotti AL; Caruso G; Cavaliere C; Piovesana S; Samperi R; Laganà A
    Anal Chim Acta; 2013 May; 776():57-63. PubMed ID: 23601281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ecotoxicology goes MudPIT?
    Uleberg KE; Larssen E; Oysæd KB; Mæland M; Bjørnstad-Hjelle A
    Mar Environ Res; 2010; 69 Suppl():S34-6. PubMed ID: 20403633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of uranyl binding proteins from human kidney-2 cell extracts by immobilized uranyl affinity chromatography and mass spectrometry.
    Dedieu A; Bérenguer F; Basset C; Prat O; Quéméneur E; Pible O; Vidaud C
    J Chromatogr A; 2009 Jul; 1216(28):5365-76. PubMed ID: 19501829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Compound immobilization and drug-affinity chromatography.
    Rix U; Gridling M; Superti-Furga G
    Methods Mol Biol; 2012; 803():25-38. PubMed ID: 22065216
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Orbitrap mass spectrometry.
    Zubarev RA; Makarov A
    Anal Chem; 2013 Jun; 85(11):5288-96. PubMed ID: 23590404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Affinity-based proteomic profiling: problems and achievements.
    Medvedev A; Kopylov A; Buneeva O; Zgoda V; Archakov A
    Proteomics; 2012 Feb; 12(4-5):621-37. PubMed ID: 22246677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool.
    Saxena C; Bonacci TM; Huss KL; Bloem LJ; Higgs RE; Hale JE
    J Proteome Res; 2009 Aug; 8(8):3951-7. PubMed ID: 19537828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of bosutinib from 3-methoxy-4-hydroxybenzoic acid.
    Yin XJ; Xu GH; Sun X; Peng Y; Ji X; Jiang K; Li F
    Molecules; 2010 Jun; 15(6):4261-6. PubMed ID: 20657439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteomic analysis of Nipponia nippon (ID#162).
    Oyanagi M; Kaneko K; Kaneko Y; Sasaki M; Nishida C; Matsuda Y; Mitsui T
    Anim Sci J; 2014 Aug; 85(8):814-32. PubMed ID: 24961376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proteomics-based strategies in kinase drug discovery.
    Bantscheff M; Hopf C; Kruse U; Drewes G
    Ernst Schering Found Symp Proc; 2007; (3):1-28. PubMed ID: 18512284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity.
    Levinson NM; Boxer SG
    Nat Chem Biol; 2014 Feb; 10(2):127-32. PubMed ID: 24292070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the mechanism of action of pyrrolo[3,2-
    Unzue A; Jessen-Trefzer C; Spiliotopoulos D; Gaudio E; Tarantelli C; Dong J; Zhao H; Pachmayr J; Zahler S; Bernasconi E; Sartori G; Cascione L; Bertoni F; Śledź P; Caflisch A; Nevado C
    RSC Med Chem; 2020 Jun; 11(6):665-675. PubMed ID: 33479666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemical proteomic analysis of 6-benzylaminopurine molecular partners in wheat grains.
    Simerský R; Chamrád I; Kania J; Strnad M; Šebela M; Lenobel R
    Plant Cell Rep; 2017 Oct; 36(10):1561-1570. PubMed ID: 28688084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Artemisinins Target GABA
    Li J; Casteels T; Frogne T; Ingvorsen C; Honoré C; Courtney M; Huber KVM; Schmitner N; Kimmel RA; Romanov RA; Sturtzel C; Lardeau CH; Klughammer J; Farlik M; Sdelci S; Vieira A; Avolio F; Briand F; Baburin I; Májek P; Pauler FM; Penz T; Stukalov A; Gridling M; Parapatics K; Barbieux C; Berishvili E; Spittler A; Colinge J; Bennett KL; Hering S; Sulpice T; Bock C; Distel M; Harkany T; Meyer D; Superti-Furga G; Collombat P; Hecksher-Sørensen J; Kubicek S
    Cell; 2017 Jan; 168(1-2):86-100.e15. PubMed ID: 27916275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions.
    Martins R; Maier J; Gorki AD; Huber KV; Sharif O; Starkl P; Saluzzo S; Quattrone F; Gawish R; Lakovits K; Aichinger MC; Radic-Sarikas B; Lardeau CH; Hladik A; Korosec A; Brown M; Vaahtomeri K; Duggan M; Kerjaschki D; Esterbauer H; Colinge J; Eisenbarth SC; Decker T; Bennett KL; Kubicek S; Sixt M; Superti-Furga G; Knapp S
    Nat Immunol; 2016 Dec; 17(12):1361-1372. PubMed ID: 27798618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
    Peter B; Winter GE; Blatt K; Bennett KL; Stefanzl G; Rix U; Eisenwort G; Hadzijusufovic E; Gridling M; Dutreix C; Hoermann G; Schwaab J; Radia D; Roesel J; Manley PW; Reiter A; Superti-Furga G; Valent P
    Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.
    Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U
    Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
    Rix U; Colinge J; Blatt K; Gridling M; Remsing Rix LL; Parapatics K; Cerny-Reiterer S; Burkard TR; Jäger U; Melo JV; Bennett KL; Valent P; Superti-Furga G
    PLoS One; 2013; 8(10):e77155. PubMed ID: 24130846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.